Atea Pharmaceuticals (NASDAQ:AVIR) had its price objective lifted by research analysts at Morgan Stanley from $49.00 to $82.00 in a research report issued on Tuesday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Morgan Stanley’s price objective indicates a potential upside of 42.56% from the company’s current price.
A number of other brokerages have also commented on AVIR. JPMorgan Chase & Co. lifted their price objective on Atea Pharmaceuticals from $45.00 to $66.00 and gave the stock an “overweight” rating in a research report on Friday, January 29th. Zacks Investment Research upgraded Atea Pharmaceuticals from a “hold” rating to a “buy” rating and set a $64.00 price objective for the company in a research report on Thursday, April 8th. Five equities research analysts have rated the stock with a buy rating, Atea Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $68.00.
AVIR stock traded up $2.21 during midday trading on Tuesday, reaching $57.52. The stock had a trading volume of 6,491 shares, compared to its average volume of 310,609. The business’s fifty day moving average price is $66.88. Atea Pharmaceuticals has a twelve month low of $24.15 and a twelve month high of $94.17.
About Atea Pharmaceuticals
Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapies for severe viral diseases. The company's lead product candidate is AT-527, a novel antiviral agent for the treatment of patients infected with severe acute respiratory syndrome coronavirus 2 and is under phase 3 clinical trial.
Further Reading: Candlestick
Receive News & Ratings for Atea Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atea Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.